Fluorine-18 prostate-specific membrane antigen (PSMA)-1007 PET/CT improves locoregional staging compared with MRI in patients undergoing surgery for intermediate and high-risk prostate cancer. PSMA ...

Absence of prostate cancer events after 3 years of tailored screening in high-risk individuals with germline pathogenic variants in DNA repair genes. Diagnostic accuracy and EPE staging for MicroUS, ...

Source: Getty Images The molecular imaging modality detects metastases earlier and more accurately compared with conventional imaging and has ushered in a new era in metastasis-directed therapy. PSMA ...

A phase 3 trial found that PSMA PET-CT after equivocal MRI halves the prostate biopsy rate in men at high clinical risk for prostate cancer. In men with high clinical risk and equivocal prostate ...

Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...

Predictors of PSMA positivity at initial staging of prostate cancer. Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: A surrogate of pelvic lymph node dissection? Follow-up ...

Fluorine-18 prostate-specific membrane antigen (PSMA)-1007 PET/CT was superior to multiparametric MRI for primary locoregional staging of prostate cancer, according to results from a phase II ...

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...

New PSMA PET/CT can detect signs of prostate cancer within elderly patients without the need of a biopsy. PSMA PET/CT scans can detect signs of prostate cancer in elderly patients without the need of ...

A new study from Denmark shows for the first time that men with biochemically recurrent prostate cancer who undergo PSMA PET/CT before salvage radiotherapy have improved survival rates compared to ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.